CD79A and IgA glomerulonephritis: Tapping into the potential for cell therapy to fulfil the unmet needs of IgA nephropathy, the Gene-edited T cells combating IgA Nephropathy (GeneTIGA) consortium aims to develop CAR T and TCR-transgenic T cell therapies targeting the B cells producing abnormal IgA [88].